HER2-POSITIVE BREAST CARCINOMA
Clinical trials for HER2-POSITIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo study for HER2+ breast cancer halted early
Disease control TerminatedThis study looked at adding a drug called copanlisib to standard targeted therapy (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that had spread and had specific gene changes (PIK3CA or PTEN). The goal was to see if the combination was safe and could hel…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
App aims to tame chemo side effects in breast cancer
Symptom relief TerminatedThis study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. Ho…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: NA • Sponsor: Palleos Healthcare GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can a gut antibiotic ease Chemo's stomach woes?
Symptom relief TerminatedThis study tested the antibiotic rifaximin (Xifaxan) to see if it could reduce stomach issues like bloating, pain, and diarrhea in people with early-stage HER2-positive breast cancer receiving pertuzumab-based chemotherapy. The trial planned to enroll 20 patients but was terminat…
Matched conditions: HER2-POSITIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 26, 2026 17:49 UTC